Product information and disease descriptionProduct descriptionProduct information
Product comparison
12 evidence topics · 14 sources
Claseprubart: mechanism, route, dosing interval, and approval status
Immune globulin intravenous 10%: Gamunex-C
| Attribute | Prescribing information |
|---|---|
| Product and route | “GAMUNEX-C FlexBag, [immune globulin injection (human), 10%, caprylate/chromatography purified] for intravenous use.” |
| CIDP indication | “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.” |
| Mechanism of action in CIDP | “The precise mechanism of action in CIDP has not been fully elucidated.” |
| CIDP dosing and interval | “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2003” |
Immune globulin intravenous 10%: Privigen
| Attribute | Prescribing information |
|---|---|
| Product and route | “PRIVIGEN, Immune Globulin Intravenous (Human), 10% Liquid” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)” |
| Limitation of use in CIDP | “PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated” |
| CIDP dosing and interval | “Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |
Immune globulin intravenous 10%: Panzyga
| Attribute | Prescribing information |
|---|---|
| Product and route | “PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated.” |
| CIDP dosing and interval | “Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |
Immune globulin intravenous 10%: Gammagard Liquid
| Attribute | Prescribing information |
|---|---|
| Product | “GAMMAGARD LIQUID is an immune globulin infusion (human)” |
| CIDP indication | “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” |
| Limitation of use in CIDP | “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP.” |
| Route in CIDP | “CIDP: Intravenous (IV)” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| CIDP dosing and interval | “Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2005” |
Immune globulin subcutaneous 20%: Hizentra
| Attribute | Prescribing information |
|---|---|
| Product and route | “HIZENTRA is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid” |
| CIDP indication | “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated, but may include immunomodulatory effects.” |
| CIDP dosing | “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.” |
| CIDP dosing interval | “CIDP: Administer weekly.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2010” |
Immune globulin 10% with recombinant human hyaluronidase: HyQvia
Neonatal Fc receptor blocker: Vyvgart Hytrulo
| Attribute | Prescribing information |
|---|---|
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| CIDP indication | “chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| CIDP dosing interval | “Administer as once weekly injections.” |
| CIDP dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over approximately 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |